CureVac (NASDAQ:CVAC) Shares Down 3.7% – What’s Next?

CureVac (NASDAQ:CVAC)’s share price fell 3.7% during trading on Wednesday . The stock traded as low as $4.00 and last traded at $3.99. 98,708 shares were traded during mid-day trading, a decline of 93% from the average session volume of 1,485,596 shares. The stock had previously closed at $4.14.

CureVac Stock Performance

The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $3.31 and its two-hundred day moving average price is $3.19. The stock has a market capitalization of $861.94 million, a PE ratio of 7.00 and a beta of 2.50.

Hedge Funds Weigh In On CureVac

Several institutional investors and hedge funds have recently modified their holdings of the business. Point72 Asset Management L.P. purchased a new stake in shares of CureVac during the second quarter worth about $8,237,000. Jane Street Group LLC grew its stake in CureVac by 239.0% during the 3rd quarter. Jane Street Group LLC now owns 79,247 shares of the company’s stock valued at $235,000 after acquiring an additional 55,867 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in CureVac by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,568 shares of the company’s stock valued at $162,000 after acquiring an additional 4,425 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its stake in CureVac by 99.8% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 44,044 shares of the company’s stock worth $147,000 after purchasing an additional 21,999 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of CureVac during the 2nd quarter worth approximately $108,000. Hedge funds and other institutional investors own 17.26% of the company’s stock.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.